Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 May 20;3(7):100990.
doi: 10.1016/j.jacadv.2024.100990. eCollection 2024 Jul.

Atrial Fibrillation in Active Cancer: A BLITZ to Expect and Manage

Gerasimos Filippatos  1 , Dimitrios Farmakis  1
Affiliations
Editorial

Atrial Fibrillation in Active Cancer: A BLITZ to Expect and Manage

Gerasimos Filippatos et al. JACC Adv. .
No abstract available

Keywords: anticoagulation; atrial fibrillation; cancer.

PubMed Disclaimer

Conflict of interest statement

Dr Filippatos has received lecture fees and/or advisory and/or trial committee membership by Bayer, Boehringer Ingelheim, Servier, Novartis, Impulse Dynamics, Vifor, Medtronic, Cardior, Novo Nordisc; and research grants from the European Union. Dr Farmakis has received lecture and/or advisor board fees from AstraZeneca, Bayer, Boehringer-Ingelheim, Leo, Roche Diagnostics, and Viatris.

Figures

None
Graphical abstract
Figure 1
Figure 1
Atrial Fibrillation and Active Cancer Frequently Coexist, Partly Because of Common Risk Factors Their coexistence complicates, on the one hand, the prognosis of each other, leading to worse outcomes; on the other, it poses important challenges in clinical practice that may, in turn, lead to inappropriate anticoagulation strategies, thus increasing further morbidity and mortality. DOAC = direct oral anticoagulants; RCT = randomized controlled trials.
See this image and copyright information in PMC

Comment on

  • doi: 10.1016/j.jacadv.2024.100991

References

    1. Farmakis D., Parissis J., Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol. 2014;63:945–953. - PubMed
    1. Pastori D., Marang A., Bisson A., et al. Thromboembolism, mortality, and bleeding in 2,435,541 atrial fibrillation patients with and without cancer: a nationwide cohort study. Cancer. 2021;127:2122–2129. - PubMed
    1. Lainscak M., Dagres N., Filippatos G.S., Anker S.D., Kremastinos D.T. Atrial fibrillation in chronic non-cardiac disease: where do we stand? Int J Cardiol. 2008;128:311–315. - PubMed
    1. Pilleron S., Sarfati D., Janssen-Heijnen M., et al. Global cancer incidence in older adults, 2012 and 2035: a population-based study. Int J Cancer. 2019;144:49–58. - PubMed
    1. Hindricks G., Potpara T., Dagres N., et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42:373–498. - PubMed

Publication types

LinkOut - more resources